Royal College of Surgeons in Ireland
FDG-PET in thyroid papillary carcinoma. a case report.pdf (156.37 kB)

FDG-PET in thyroid papillary carcinoma: a case report

Download (156.37 kB)
journal contribution
posted on 2023-05-18, 15:22 authored by Johnny Chun Lin Kwok, Bing-Fu Shih, Ming-Tse Wu, Tsing-Ho Tsao, Gu-Hong Lin

The most common form of thyroid cancer is papillary thyroid cancer, accounting for 70-90% of well differentiated thyroid malignancies. The incidence of malignant thyroid tumours is approximately 4/100,000 in women and 1.5/100,000 in men. In recent years, there has been an increase in the incidence of papillary carcinoma; whether this is due to dietary changes over time remains unclear. Although papillary tumours tend to metastasise via lymphatics, they have a good prognosis, with a 90% 10-year survival rate. Positron emission tomography (PET) with the glucose analogue fluorodeoxyglucose (FDG-PET) has a special place in the investigation of papillary thyroid malignancies. These tumours are generally poorly differentiated and have impaired Na+/I- pumps, resulting in poor iodine uptake. However, these tumour cells have an increased expression of GLUT-1 and GLUT-3 glucose transporters. FDG is a glucose analogue that does not enter glycolysis, and so papillary tumour cells accumulate FDG, leading to positive findings on PET. Therefore, FDG-PET is especially important in cases where an iodine 131 (131I) scan is negative but serum thyroglobulin levels remain high. In this scenario, FDG-PET sensitivity has been shown to be greater than 90%.



The original article is available at Part of the RCSIsmj collection 2007-8

Published Citation

Kwok JCL, Shih BF, Wu MT, Tsao TH, Lin GH. FDG-PET in thyroid papillary carcinoma. a case report. RCSIsmj. 2008;1(1):31-33

Publication Date



  • Undergraduate Research


RCSI University of Medicine and Health Sciences


  • Published Version (Version of Record)